Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boehringer’s Novel Exercise Claims In COPD May Spur FDA Action To Clarify Requirements

Executive Summary

Company was hoping for an exercise tolerability claim for olodaterol, but members of the Pulmonary-Allergy Drugs Advisory Committee questioned several aspects of the trials and suggested FDA issue guidance on the matter.


Related Content

Striverdi Exercise Trials Tried, But Failed, To Control For Non-Disease Impacts
Novel COPD Exercise Claims Eluded Boehringer In Bid to Differentiate Striverdi
Boehringer’s Striverdi Respimat Approved For COPD, But Without Exercise Claim
Breo Inverts Traditional Path To COPD Indication For LABA Combinations
COPD Market Snapshot: New Products, Limited Differentiation
New COPD Candidates Could Get Hung Up On Safety Concerns
BI’s Olodaterol Wants Novel Exercise Claims In COPD
FDA Supersizes Its Order For LABA Safety Studies


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts